APPLICATION
ANDA207626
TYPE
ANDA
ORIGINAL APPROVAL
2019-04-09
LATEST ACTION
2025-01-14
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
ROSUVASTATIN CALCIUMPrescription
ROSUVASTATIN CALCIUM EQ 40MG BASE · TABLET · ORAL
ROSUVASTATIN CALCIUMPrescription
ROSUVASTATIN CALCIUM EQ 10MG BASE · TABLET · ORAL
ROSUVASTATIN CALCIUMPrescription
ROSUVASTATIN CALCIUM EQ 20MG BASE · TABLET · ORAL
ROSUVASTATIN CALCIUMPrescription
ROSUVASTATIN CALCIUM EQ 5MG BASE · TABLET · ORAL
Approval history
2025-01-14Labeling · Supplement 8 · standardAP
2025-01-14Labeling · Supplement 22 · standardAP
2025-01-14Labeling · Supplement 12 · standardAP
2025-01-14Labeling · Supplement 10 · standardAP
2025-01-14Labeling · Supplement 7 · standardAP
2025-01-14Labeling · Supplement 3 · standardAP
2019-04-09UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.